Year: 2014
Type: article
Study design: Observational Study
Abstract: // Eva Giesen 1,* , Lucia B. Jilaveanu 1,* , Fabio Parisi 2 , Yuval Kluger 2 , Robert L. Camp 2 and Harriet M. Kluger 1 1 Yale Cancer Center, Yale University School of Medicine, New Haven, CT, U.S 2 Department of Pathology, Yale University School of Medicine, New Haven, CT, U.S * These authors contributed equally to this work Correspondence: Harriet M. Kluger , email: // Keywords : Cancer Testis Antigens, drug targets, kidney cancer, clear cell carcinoma, adoptive cell therapy Received : April 15, 2014 Accepted : June 12, 2014 Published : June 13, 2014 Abstract Background: Novel immune therapies targeting tumor specific antigens are being developed. Our purpose was to determine expression of the cancer testes antigen NY-ESO-1 in renal cell carcinoma (RCC), as NY-ESO-1 targeting approaches, particularly adoptive cell therapy, have not been evaluated in this disease. Methods: We employed tissue microarrays containing >300 unique RCC cases and adjacent benign renal tissue to determine NY-ESO-1 expression using a quantitative immunofluorescence method. In addition, we studied NY-ESO-1 expression in 35 matched primary and metastatic RCC specimens to assess concordance between different tumor sites. Results: NY-ESO-1 was highly expressed in a subset of RCCs. Expression in primary RCC specimens was significantly higher than adjacent normal renal tissue (P<0.0001) and higher in clear cell carcinomas than papillary RCC (P<0.0001). Expression levels in metastatic specimens were higher than in matched primary samples (P=0.0018), and the correlation between the two sites was modest (χ 2 =3.5, p=0.06). Conclusions: Aberrant NY-ESO-1 expression seen in clear cell RCC suggests that NY-ESO-1 targeting approaches should be studied in this disease. Expression is higher in metastatic sites, and discordance between primary and metastatic sites in some patients suggests that patient selection for these therapies should be based on expression in metastatic rather than nephrectomy specimens.
Source: Oncotarget
Authors: Eva Giesen, Lucia B. Jilaveanu, Fabio Parisi, Yuval Kluger, Robert L. Camp, Harriet M. Kluger
Institutions: Yale Cancer Center, Yale University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W1936820080